81 related articles for article (PubMed ID: 14603338)
1. BRAF mutations in acute leukemias.
Lee JW; Soung YH; Park WS; Kim SY; Nam SW; Min WS; Lee JY; Yoo NJ; Lee SH
Leukemia; 2004 Jan; 18(1):170-2. PubMed ID: 14603338
[No Abstract] [Full Text] [Related]
2. Absence of exon 15 BRAF germline mutations in familial melanoma.
Lang J; Boxer M; MacKie R
Hum Mutat; 2003 Mar; 21(3):327-30. PubMed ID: 12619120
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract][Full Text] [Related]
4. Mutation of BRAF is uncommon in AML FAB type M1 and M2.
Smith ML; Snaddon J; Neat M; Cambal-Parrales M; Arch R; Lister TA; Fitzgibbon J
Leukemia; 2003 Jan; 17(1):274-5. PubMed ID: 12529696
[No Abstract] [Full Text] [Related]
5. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
6. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Stoehr R; Brinkmann A; Filbeck T; Gamper C; Wild P; Blaszyk H; Hofstaedter F; Knuechel R; Hartmann A
Oncol Rep; 2004 Jan; 11(1):137-41. PubMed ID: 14654916
[TBL] [Abstract][Full Text] [Related]
7. Mutant form of BRAF gene in blood plasma of cancer patients.
Vdovichenko KK; Markova SI; Belokhvostov AS
Ann N Y Acad Sci; 2004 Jun; 1022():228-31. PubMed ID: 15251965
[No Abstract] [Full Text] [Related]
8. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
9. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.
Knobbe CB; Reifenberger J; Reifenberger G
Acta Neuropathol; 2004 Dec; 108(6):467-70. PubMed ID: 15517309
[TBL] [Abstract][Full Text] [Related]
10. Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP.
Dote H; Tsukuda K; Toyooka S; Yano M; Pass HI; Shimizu N
Oncol Rep; 2004 Feb; 11(2):361-3. PubMed ID: 14719068
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutations in an Italian cohort of thyroid cancers.
Fugazzola L; Mannavola D; Cirello V; Vannucchi G; Muzza M; Vicentini L; Beck-Peccoz P
Clin Endocrinol (Oxf); 2004 Aug; 61(2):239-43. PubMed ID: 15272920
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
Fransén K; Klintenäs M; Osterström A; Dimberg J; Monstein HJ; Söderkvist P
Carcinogenesis; 2004 Apr; 25(4):527-33. PubMed ID: 14688025
[TBL] [Abstract][Full Text] [Related]
13. Mutations of p53 gene in gastric carcinoma in Taiwan.
Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutations in conjunctival melanoma.
Gear H; Williams H; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.
Saetta AA; Papanastasiou P; Michalopoulos NV; Gigelou F; Korkolopoulou P; Bei T; Patsouris E
Virchows Arch; 2004 Aug; 445(2):179-82. PubMed ID: 15221372
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
[TBL] [Abstract][Full Text] [Related]
17. Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms.
Miao J; Kusafuka T; Fukuzawa M
Oncol Rep; 2004 Dec; 12(6):1269-72. PubMed ID: 15547749
[TBL] [Abstract][Full Text] [Related]
18. The JAK2 V617F mutation in de novo acute myelogenous leukemias.
Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; Rhim HS; Min WS; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
Oncogene; 2006 Mar; 25(9):1434-6. PubMed ID: 16247455
[TBL] [Abstract][Full Text] [Related]
19. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Deichmann M; Thome M; Benner A; Näher H
Oncology; 2004; 66(5):411-9. PubMed ID: 15331929
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
